Faculty of Biology, Medicine and Health

The University of Manchester

This project is no longer listed on FindAPhD.com and may not be available.

Click here to search FindAPhD.com for PhD studentship opportunities

  (MBRC) Identification of common genetic modifiers of risk of vestibular schwannoma (acoustic neuroma)

  Prof G Evans, Dr M Smith  No more applications being accepted  Funded PhD Project (European/UK Students Only)

About the Project

Vestibular schwannomas arise from the 8th cranial nerve and are normally isolated tumours that occur in older adults. Bilateral vestibular schwannomas are a hallmark of neurofibromatosis type 2 (NF2) disease. Vestibular schwannomas carry a lifetime risk of balance problems and profound to complete hearing loss, requiring treatment by hearing aids or rehabilitation with auditory brainstem/cochlear implants1. Surgery is used to remove vestibular schwannomas where possible, and radiation is used for sporadic vestibular schwannomas when they have surgical morbiditiesor with patient choice; however, the outcome of radiation therapy is worse for individuals with NF2-associated vestibular schwannomas than for those with a sporadic tumour. Vestibular schwannomas have a low rate of association with predisposing mutations2, but those occurring in within the context of NF2 disease tend to occur earlier in life. In addition, our recent studies have identified new areas of clinical phenotypic overlap between NF2 disease and LZTR1-associated schwannomatosis3,4, indicating that LZTR1 mutations can cause unilateral vestibular schwannoma. Vestibular schwannomas have traditionally been included in the exclusion criteria for diagnosis of schwannomatosis. These studies highlight the importance of genetic diagnosis, which in some cases can be the only way to distinguish between sporadic vestibular schwannoma, mosaic NF2 and LZTR1-associated schwannomatosis, and indicate the usefulness of stratifying risk for age at onset.

Our current study will determine genetic modifiers for risk of earlier age at onset of VS and identify novel mechanisms of schwannoma initiation. This will aid clinical management of affected individuals with a particular genetic variant or a particular set of risk variants and may identify members of the general population at high risk of VS that warrants MRI screening.


Funding Notes

Applicants must have obtained, or be about to obtain, at least an upper second class honours degree (or equivalent) in a relevant subject.

Applicants must be from the UK/EU and funding covers fees/stipend for three years commencing September 2018. Applicants may contact the Primary Supervisor directly with any questions. Online applications must be submitted, select 'Manchester BRC' as the programme - for more information on how to apply please visit https://www.bmh.manchester.ac.uk/study/research/funded-programmes/mbrc-studentships/

References

1. Evans DG, Moran A, King A, Saeed S, Gurusinghe N, Ramsden R. Incidence of vestibular schwannoma and neurofibromatosis 2 in the North West of England over a 10-year period: higher incidence than previously thought. Otol Neurotol. Jan 2005;26(1):93-97
2. Pathmanaban ON, Sadler KV, Kamaly-Asl ID, King AT, Rutherford SA, Hammerbeck-Ward C, McCabe MG, Kilday JP, Beetz C, Poplawski NK, Evans DG, Smith MJ. Association of Genetic Predisposition With Solitary Schwannoma or Meningioma in Children and Young Adults. JAMA Neurol. 2017;74(9):1123-1129.
3. Smith MJ, Isidor B, Beetz C, Williams SG, Bhaskar SS, Richer W, O'Sullivan J, Anderson B, Daly SB, Urquhart JE, Fryer A, Rustad CF, Mills SJ, Samii A, du Plessis D, Halliday D, Barbarot S, Bourdeaut F, Newman WG, Evans DG. Mutations in LZTR1 add to the complex heterogeneity of schwannomatosis. Neurology. Jan 13 2015;84(2):141-147.
4. Smith MJ, Bowers NL, Bulman M, Gokhale C, Wallace AJ, King AT, Lloyd SK, Rutherford SA, Hammerbeck-Ward CL, Freeman SR, Evans DG. Revisiting neurofibromatosis type 2 diagnostic criteria to exclude LZTR1-related schwannomatosis. Neurology. 2017;88:87-92.

Open Days


Where will I study?

Faculty of Biology, Medicine and Health

Tackle real world challenges, make a difference, and elevate your career with postgraduate research in the Faculty of Biology, Medicine and Health at Manchester. From biochemistry to neuroscience, cancer sciences to medicine, audiology to mental health and everything in between, we offer a wide range of postgraduate research projects, programmes and funding which will allow you to immerse yourself in an area of research you’re passionate about.

Why study at Faculty of Biology, Medicine and Health?

Ranked the best place to live in the UK (The Economist Global Liveability Index, 2022), Manchester boasts world-class culture, iconic sports, a thriving music and food scene, and much more. It's not just a place to research, it's a place to call home.

Experience PhD life as part of a diverse postgraduate research community of more than 1,000 postgraduate researchers at the 29th most international university in the world (Times Higher Education, 2023).

With 93% of research activity at the University rated as 'world-leading' or 'internationally excellent' (Research Excellence Framework, 2021), you'll get the chance to have an impact on global health and science challenges.

1000+

postgraduate students

220

PhDs

6

ranked in UK - QS (2025)

Manchester  United Kingdom

main campus

Upcoming Open Days & Webinars


About Faculty of Biology, Medicine and Health

At Manchester, postgraduate researchers are at the heart of our mission to tackle pressing global challenges in biological, medical and healthcare sciences - and you could be too.

By choosing Manchester for your postgraduate research, you’ll be joining a university with an exceptional research reputation, where 93% of research is world-leading or internationally excellent (REF, 2021) and where your work will have real-world impact.

You’ll research in world-class facilities alongside leading experts at the forefront of innovation, collaborating across disciplines to pioneer new treatments, advance scientific knowledge, and improve healthcare globally.

Supported by our dedicated Doctoral Academy and strong industry links, you'll experience PhD life in a vibrant, welcoming and diverse postgraduate research community.

And you’ll leave with the specialist knowledge, research experience and transferable skills that will shape your future in academia, research or industry.





Main campus

The University of Manchester

Manchester

North West

United Kingdom

PhD saved sucessfully

(International Partnership Studentship) Using white matter network alterations relating to stroke risk to predict cognitive and health outcomes

The project aims to investigate how age-related changes in brain white matter impact upon cognitive and health outcomes. Using advanced software and MRI data from the UK Biobank, the researchers will create effective cross-sectional and longitudinal models of how white matter abnormalities predict cognitive function. Read more
More details

(MB-PhD) Gene regulatory networks driving metastatic progression in oesophageal adenocarcinoma

Oesophageal adenocarcinoma (OAC) incidence is increasing and yet survival rates remain very poor. There are limited treatment options, especially for metastatic disease, which is especially problematic as patients usually present with late stage disease. Read more
More details

(MB-PhD) MYST Histone Acetyltransferases as Therapeutic Targets in Acute Myeloid Leukaemia

Cytotoxic chemotherapy has been the standard of care for treatment of acute myeloid leukaemia (AML) for the last 50 years. Unfortunately, more often than not, it fails to cure patients, and the 5 years survival rate for all-comers with AML is only around 20%. Read more
More details

(MB-PhD)Immunomodulation in multiple myeloma

Multiple myeloma is a devastating B-cell malignancy for which there is no cure. The development of immunomodulatory drugs (IMiDs) has proved transformative to multiple myeloma care, however, their remain unanswered questions related to the mechanism of action of this important drug class. Read more
More details

(MRC DTP CASE) Developing a cortical organoid model of genetic autism to understand early brain development

Neurodevelopmental conditions including autism and ADHD affect 4-8% of the paediatric population. These conditions present in the preschool period, are highly heritable and can severely affect quality of life, academic and occupational functioning. Read more
More details

(MRC DTP CASE) Drug Binding on human G-Protein Coupled Receptors under Tension-Altered Biomechanics in Diseases

Integral membrane proteins (MPs) constitute a significant part of the genome and are targets of ~30% of therapeutics. However, structural and functional understanding of these proteins often lags behind that of their soluble counterparts. Read more
More details

(MRC DTP) Circadian mechanisms in psoriasis: translating genomic and computational analysis to clinical care.

Despite numerous lines of evidence supporting a role for the circadian clock regulating multiple immunological axes, the dominant cell type driving rhythmic disease expression in psoriasis remains undetermined and there has been no progress on time-of-day regulation of psoriasis. Read more
More details

(MRC DTP) Combinatorial targeting of multiple disease mechanisms in drug-resistant epilepsy using microRNA inhibitors

Epilepsy is one of the most common chronic neurological diseases, affecting ~70 million people worldwide. Epilepsy is characterised by susceptibility to spontaneous seizures, and can also include challenges with cognition, sleep and mental health. Read more
More details

(MRC DTP) Controlling G-protein coupled receptors to understand and treat obesity

The socioeconomic burden of obesity is ever increasing. Therefore, deciphering the neural substrates that control energy intake, expenditure and partitioning is an important step to developing novel treatments to reduce obesity rates. Read more
More details

(MRC DTP) Decoding the Brain-Immune Axis: Neuronal Circuitry and Metabolic Impact on Immune Responses

The immune system's response is intricately linked to nutritional status, with fasting and caloric restriction reducing inflammatory damage and extreme dietary perturbations increasing susceptibility to infection and inflammatory disorders. Read more
More details

(MRC DTP) Developing novel therapeutics to target splicing factor mutant myeloid malignancies

Aberrant RNA splicing is a key pathogenic event in several cancers including blood cancers. Blood cancer patients with splice factor mutations have worse overall survival than splice factor wild-type patients, highlighting the need for better treatment strategies for this group of patients. Read more
More details

(MRC DTP) Dissecting immune networks in barrier tissues and beyond

The immune system maintains tissue health within a variety of tissues and organs throughout the body, from mucosal barrier sites (such as the oral cavity, gut and lung) to the membranes that line the brain (meninges). Read more
More details